Project: Targets and biomarkers of the novel anticancer compounds inducing oxidative stress in cancer cells
| Acronym | OxidoCurin (Reference Number: 11481) |
| Duration | 01/08/2017 |
| Project Topic | We will further develop the novel anti-cancer lead compound LCTA2290 and its analogs: 1) Experimentally validate the target, identified during the first phase of the project – thioredoxin reductase 1 (TrxR1); 2) Identify the additional target(s) using state-of the-art TPP methodology; 2) Elucidate the mechanism of interaction of lead compound with the target(s) and the mechanism of action; 4) Identify biomarkers of sensitivity and resistance of cancer cells and the mechanism of possible toxicity |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 7 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | geneXplain GmbH | Coordinator | Germany |
| 2 | HDxperts AB | Partner | Sweden |
| 3 | Karolinska Institute | Partner | Sweden |